ATNF

NASDAQ

180 Life Sciences Corp.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2017

News25/Ratings1

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.

Latest news

25 items

240dSEC
SEC Form PRE 14A filed by 180 Life Sciences Corp.
PRE 14A - ETHZilla Corp (0001690080) (Filer)
241dINSIDER
Chief Executive Officer Jordan Blair disposed of 200,000 shares (SEC Form 4)
4 - ETHZilla Corp (0001690080) (Issuer)
241dSEC
180 Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - ETHZilla Corp (0001690080) (Filer)
244dSEC
180 Life Sciences Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - ETHZilla Corp (0001690080) (Filer)
244dSEC
SEC Form 424B5 filed by 180 Life Sciences Corp.
424B5 - ETHZilla Corp (0001690080) (Filer)
244dSEC
SEC Form S-3ASR filed by 180 Life Sciences Corp.
S-3ASR - ETHZilla Corp (0001690080) (Filer)
244dSEC
SEC Form S-3ASR filed by 180 Life Sciences Corp.
S-3ASR - ETHZilla Corp (0001690080) (Filer)
244dSEC
SEC Form S-3ASR filed by 180 Life Sciences Corp.
S-3ASR - ETHZilla Corp (0001690080) (Filer)
246dSEC
180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities
8-K - ETHZilla Corp (0001690080) (Filer)
246dSEC
Amendment: 180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K/A - ETHZilla Corp (0001690080) (Filer)
248dINSIDER
Former 10% Owner Elray Resources, Inc. sold $9,278,586 worth of shares (2,998,000 units at $3.09) and exercised 3,000,000 in-the-money shares at a strike of $1.68, increasing direct ownership by 0.15% to 1,320,000 units (SEC Form 4)
4 - ETHZilla Corp (0001690080) (Issuer)
248dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by 180 Life Sciences Corp.
SCHEDULE 13D/A - ETHZilla Corp (0001690080) (Subject)
248dSEC
180 Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - ETHZilla Corp (0001690080) (Filer)
248dPR
ETHZilla Unveils New Brand Committed to Advancing Ethereum Treasury Strategy
Company announces new ticker (formally ATNF) and will begin trading on NASDAQ under ETHZ on August 18, 2025 Company has accumulated 94,675 ETH at an average acquisition price of $3,902.20, which is now valued at approximately $419 million PALM BEACH, Fla., Aug. 18, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), (the "Company" or "ETHZilla"), today announced the official launch of its new brand as part of the Company's transition to focus on its recently announced Ethereum treasury strategy. Previously operating as 180 Life Sciences Corp., ETHZilla will focus a significant portion of its non-legacy operations on becoming an accumulation vehicle for Ether (ETH) that is built for the
248dSEC
Amendment: 180 Life Sciences Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K/A - ETHZilla Corp (0001690080) (Filer)
252dSEC
SEC Form 144 filed by 180 Life Sciences Corp.
144 - 180 Life Sciences Corp. (0001690080) (Subject)
253dSEC
SEC Form 424B5 filed by 180 Life Sciences Corp.
424B5 - 180 Life Sciences Corp. (0001690080) (Filer)
253dSEC
180 Life Sciences Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
253dSEC
180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
254dINSIDER
SEC Form 4 filed by Executive Chairman Rudisill Mcandrew
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
254dINSIDER
SEC Form 3 filed by new insider Heter Crystal Jane
3 - 180 Life Sciences Corp. (0001690080) (Issuer)
254dSEC
SEC Form SCHEDULE 13G filed by 180 Life Sciences Corp.
SCHEDULE 13G - 180 Life Sciences Corp. (0001690080) (Subject)
254dSEC
180 Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
254dPR
180 Life Sciences (ETHZilla) Holds 82,186 ETH
Company Initiates Institutional ETH Accumulation Strategy PALO ALTO, Calif., Aug. 12, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), dba ETHZilla (the "Company", "180 Life Sciences" or "ETHZilla"), announced today that is has total holdings of 82,186 Ether ("ETH") at an average acquisition price of $3,806.71, which is now valued at approximately $349 million. In addition to the ETH, ETHZilla holds approximately $238 million in USD cash equivalents. "At ETHZilla we have put over $350 million in capital to work since the PIPE transaction we completed last week, and
255dINSIDER
SEC Form 4 filed by Director Shoemaker Stephen H
4 - 180 Life Sciences Corp. (0001690080) (Issuer)